Our Mission

A New Approach

We target cancer-specific phenotypes.

The incurability of metastatic cancer stems largely from therapeutic resistance to molecularly targeted approaches, which in turn is driven by genetic instability. Current therapeutic approaches based on targeting individual, specific mutations address a small fraction of metastatic patients. Genetic instability induces rapid variations in the molecular presentations of cancer metastases, which further reduces the applicability of molecularly targeted therapeutics.

At BrYet, we target cancer-specific phenotypes, which are largely independent of molecular subtypes and the evolution of their mutational profile. Our current primary focus is on the cancer phenotypes that are based on molecular transport differentials across biological barriers. These transport differentials are shared across cancers, regardless of molecular subtypes, and are less impacted by genetic instability. The physics of mass transport is largely indifferent to genetic instability, retaining the same characteristics and vulnerabilities regardless of the evolution of the mutational profile, since it is largely dictated by the biology of the tissue to which cancer is metastasized. This allows us to effectively target lung and liver metastases originating from a broad spectrum of body sites, focusing on the transport properties that are conserved across them, and remain the same even at different stages of their evolution.

Employing our proprietary methods for phenotype targeting, our first drug, ML-016, has been proven to yield long-term, effective functional cures to devastating presentations of metastases to the lung and liver in 40-50% of treated preclinical animal models. Even those that suffered relapse had much longer survival times than those treated with conventional cancer therapies.